Literature DB >> 3263817

Detection of gangliosides of the GM1b type on high-performance thin-layer chromatography plates by immunostaining after neuraminidase treatment.

J Müthing1, P F Mühlradt.   

Abstract

A method for the detection of GM1b-type gangliosides in complex mixtures of gangliosides was developed. The procedure involves separation of gangliosides on high-performance thin-layer chromatography plates, fixation of the silica gel, treatment with neuraminidase from Vibrio cholerae in the absence of detergent, and incubation of the plates with GgOse4Cer-specific antibodies. Alkaline phosphatase-conjugated second antibodies are used to visualize bound first antibodies by generating a blue dye from 5-bromo-4-chloro-3-indolylphosphate. The procedure is capable of detecting as little as 30 ng of gangliosides. Gangliosides from murine T lymphocytes and from human brain served as examples. Besides GM1b, GD1 alpha is also detectable by this method, whereas the human brain gangliosides GM1a, GD1a, GD1b, and GT1b are not, because they are neuraminidase resistant. Since terminally sialylated gangliosides such as GM1b were described as virus receptors, and certain other terminally sialylated gangliosides are discussed as tumor markers, this method should be useful to screen gangliosides from different tissues or cell lines for the presence of such components, especially if only small amounts of material are available.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263817     DOI: 10.1016/0003-2697(88)90151-0

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  10 in total

1.  Ganglioside expression in tissues of mice lacking beta2-microglobulin.

Authors:  A Markotić; A Marusić; J Tomac; J Müthing
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

2.  The different inhibiting effect of cholera toxin on two leukemia cell lines does not correlate with their toxin binding capacity.

Authors:  A Giuliani; E Calappi; E Mineo; M G Neri; A Gallina; A Pessina
Journal:  Mol Cell Biochem       Date:  1995-11-22       Impact factor: 3.396

3.  Neutral glycosphingolipids and gangliosides from spleen T lymphoblasts of genetically different inbred mouse strains.

Authors:  J Müthing
Journal:  Glycoconj J       Date:  1997-02       Impact factor: 2.916

4.  Glycosphingolipid expression in human skeletal and heart muscle assessed by immunostaining thin-layer chromatography.

Authors:  J Müthing; M Cacić
Journal:  Glycoconj J       Date:  1997-01       Impact factor: 2.916

5.  The ganglioside GD1 alpha' IV3Neu5Ac, III6Neu5Ac-GgOse4Cer, is a major disialoganglioside in the highly metastatic murine lymphoreticular tumour cell line MDAY-D2.

Authors:  J Müthing; J Peter-Katalinić; F G Hanisch; F Unland; J Lehmann
Journal:  Glycoconj J       Date:  1994-04       Impact factor: 2.916

6.  Structural studies of gangliosides from the YAC-1 mouse lymphoma cell line by immunological detection and fast atom bombardment mass spectrometry.

Authors:  J Müthing; J Peter-Katalinić; F G Hanisch; U Neumann
Journal:  Glycoconj J       Date:  1991-10       Impact factor: 2.916

7.  Expression of neutral glycosphingolipids and gangliosides in human skeletal and heart muscle determined by indirect immunofluorescence staining.

Authors:  M Cacić; J Müthing; I Kracun; U Neumann; S Weber-Schürholz
Journal:  Glycoconj J       Date:  1994-10       Impact factor: 2.916

8.  C-series polysialogangliosides are expressed on stellate neurons of adult human cerebellum.

Authors:  M Heffer-Lauc; M Cacić; D Serman
Journal:  Glycoconj J       Date:  1998-04       Impact factor: 2.916

9.  Significant inhibition of hybridoma cells by exogenous application of ganglioside GM3, a possible modulator of cell growth in vitro.

Authors:  H Brandt; J Müthing; J Peter-Katalinić; J Lehmann
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

10.  Ganglioside alterations in YAC-1 cells cultivated in serum-supplemented and serum-free growth medium.

Authors:  J Müthing; A Pörtner; V Jäger
Journal:  Glycoconj J       Date:  1992-10       Impact factor: 2.916

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.